Methicillin-Resistant Staphylococcus aureus Epidemiology
DRG Epidemiology's coverage of methicillin-resistant staphylococcus aureus (MRSA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of methicillin-resistant staphylococcus aureus for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's MRSA forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of MRSA events per year?
Of all people diagnosed with MRSA, how many in each country across the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MRSA over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to Microsoft Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following MRSA patient populations:
Diagnosed MRSA Events by Treatment
Diagnosed MRSA Events
Diagnosed MRSA Events – BSI
Diagnosed MRSA Events – cIAI
Diagnosed MRSA Events – SSSI
Diagnosed MRSA Events – HAP
Diagnosed MRSA Events – HCAP
Diagnosed MRSA Events – NP
Diagnosed MRSA Events – SSI
Diagnosed MRSA Events – SSSI & cSSSI
… and more (details available on request).
Note: coverage may vary by country and region.